Cipla's stock is trading at Rs 1508.1, reflecting a decrease of 0.57% today, with an average daily volatility of 3.0381 noted in the last three months.

Hi there, Naugatuck! We've got your morning read ready! Read on to stay connected. ☕️️ In today's newsletter: Also on today's calendar: How new tax law changes may impact you - evening and lunchtime ...

Adding stenting to intensive medical therapy significantly improves outcomes among patients with asymptomatic high-grade carotid stenosis compared with drug treatment alone, a bar not met by carotid ...

CAS plus intensive medical therapy significantly reduced 4-year stroke or death rates compared with medical therapy alone. CEA did not provide a significant additional benefit over intensive medical ...

Deepens partnership with COPD Foundation to drive patient awareness and engagement Building on nine decades of 'Caring for Life' globally and ten years of impact in the U.S., Cipla continues to ...

The average daily trading volume for FutureCrest Acquisition (FCRS) is 263,727. The opening price for FutureCrest Acquisition today was 10.13.

Global CEO & MD Umang Vohra to step down in March end Global COO Achin Gupta to take over Cipla should focus on innovation over next 5-to-7 years - Vohra Beats second-quarter profit view Oct 30 ...

Eli Lilly (NYSE:LLY) has partnered with India's Cipla to market its weight-loss medication Tirzepatide under a new brand in the country. According to the agreement announced by the companies, Lilly ...

Gilead Sciences Inc. ended its Biktarvy patent lawsuit with Cipla Ltd., reaching a settlement that bars US copies of the HIV therapy until April 2036. Gilead reached similar settlements last month ...